Chicago, IL 60637
United States
Cholangiocarcinoma; IDH1 mutation; Ivosidenib; Phase 3 study
FGR2, fusion; rearrangement; pemigatinib; INCB054828; intrahepatic cholangiocarcinoma; cholangiocarcinoma; biliary tract cancer